Sun Pharma's partner Philogen reported that Fibromun's Phase II FLASH (STS) and GLIOSTAR (glioblastoma) trials both failed to meet their primary endpoints.
Nidlegy's Phase II Duncan study showed 52.6% complete pathological responses in BCC; three new registrational studies in BCC and cSCC planned for Q2 2026.
FDA Type C meeting in March 2026 aligned on regulatory pathway for Nidlegy melanoma approval in the US, subject to ongoing Phase III trial completion.
FIBROSARC-2 Phase III study design under parallel FDA/EMA scientific advice, conclusion expected Q2 2026; GLIOSTELLA survival data expected September 2026.